This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Celltrion Healthcare Co., Ltd.
Celltrion Healthcare Co., Ltd., headquartered in South Korea (KR), is a prominent player in the biopharmaceutical industry, specialising in the development and manufacturing of biosimilars and innovative therapeutics. Founded in 2002, the company has achieved significant milestones, including the successful launch of its first biosimilar, Remsima, which has gained global recognition. With a strong operational presence in Europe, the Americas, and Asia, Celltrion Healthcare focuses on providing high-quality, cost-effective treatment options for various diseases, including autoimmune disorders and cancer. Its core products, characterised by their unique formulation and rigorous quality standards, have positioned the company as a leader in the biosimilar market. Notably, Celltrion has received numerous accolades for its contributions to healthcare, reinforcing its commitment to improving patient outcomes worldwide.
DitchCarbon Score
How does Celltrion Healthcare Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Celltrion Healthcare Co., Ltd.'s score of 30 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Celltrion Healthcare Co., Ltd., headquartered in South Korea (KR), currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Celltrion, Inc., which may influence its climate commitments and reporting practices. As of now, Celltrion Healthcare has not established any documented reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of specific emissions data and reduction targets suggests that the company may still be in the early stages of formalising its climate strategy. The emissions data and performance metrics may be inherited from its parent company, Celltrion, Inc., which could provide a broader context for understanding its environmental impact. However, without specific figures or commitments, it is challenging to assess the company's current standing in terms of carbon emissions and climate action. In summary, while Celltrion Healthcare Co., Ltd. is part of a larger corporate family that may have climate initiatives, it currently lacks publicly available emissions data and defined reduction targets.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 16,864,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 31,667,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Celltrion Healthcare Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
